Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluorouracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2′-deoxyuridine-5′-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.
Fluorouracil (5-FU) is a pyrimidine analog used as an antineoplastic agent to treat multiple solid tumors including colon, rectal, breast, gastric, pancreatic, ovarian, bladder, and liver cancer. Fluorouracil is associated with a low rate of transient serum aminotransferase elevations during therapy and has been implicated in rare cases of clinically apparent acute liver injury.
Mechanism of Action
The precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5–10-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex. This results in the inhibition of the formation of thymidylate from uracil, which leads to the inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.
or
5-FU requires enzymatic conversion to the nucleotide (ribosylation and phosphorylation) in order to exert its cytotoxic activity. Several routes are available for the formation of the 5′-monophosphate nucleotide (F-UMP) in animal cells. 5-FU may be converted to fluorouridine by uridine phosphorylase and then to F-UMP by uridine kinase, or it may react directly with 5-phosphoribosyl-1-pyrophosphate (PRPP), in a reaction catalyzed by orotate phosphoribosyl transferase, to form F-UMP. Many metabolic pathways are available to F-UMP, including incorporation into RNA. A reaction sequence crucial for antineoplastic activity involves the reduction of the diphosphate nucleotide by the enzyme ribonucleoside diphosphate reductase to the deoxynucleotide level and the eventual formation of 5-fluoro-2′-deoxyuridine-5′-phosphate (F-dUMP). 5-FU also may be converted directly to the deoxyriboside 5-FUdR by the enzyme thymidine phosphorylase and further to F-dUMP, a potent inhibitor of thymidylate synthesis, by thymidine kinase … The interaction between F-dUMP and the enzyme thymidylate synthase leads to the depletion of TTP, a necessary constituent of DNA … The folate cofactor, 5,10-methylenetetrahydrofolate, and F-dUMP form a covalently bound ternary complex with the enzyme. The inhibitory complex resembles the transition state formed during the normal enzymatic reaction when dUMP is converted to thymidylate. Although the physiological complex progresses to the synthesis of thymidylate by transfer of the methylene group and 2 hydrogen atoms from folate to dUMP, this reaction is blocked in the inhibitory complex by the stability of the fluorine carbon bond on F-dUMP; sustained inhibition of the enzyme results
Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine – which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the “S” phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme that converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.
Indications
- For the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Fluorouracil (5-FU) is a pyrimidine analog used as an antineoplastic agent to treat multiple solid tumors including colon, rectal, breast, gastric, pancreatic, ovarian, bladder, and liver cancer.
- Antimetabolites; Antimetabolites, Antineoplastic; Immunosuppressive Agents
- Fluorouracil is indicated for the palliative treatment of carcinoma of the colon, rectum, breast, stomach, and pancreas in patients considered to be incurable by surgery or other means.
- Fluorouracil is also indicated for the treatment of bladder carcinoma, prostatic carcinoma, epithelial ovarian carcinoma, cervical carcinoma, endometrial carcinoma, anal carcinoma, esophageal carcinoma, metastatic tumors of skin carcinoma, hepatoblastoma, and is used by intra-arterial injection for the treatment of hepatic tumors and head and neck tumors.
- Actinic Keratosis (AK)
- Breast Cancer
- Malignant Neoplasm of Colon
- Malignant Neoplasm of Pancreas
- Malignant Neoplasm of Stomach
- Rectal Carcinoma
- Superficial Basal Cell Carcinoma
- Verruca (Warts)
- Hyperkeratotic actinic keratosis
Use in Cancer
Fluorouracil injection is approved to treat:
Fluorouracil is also called 5-FU. Fluorouracil is also being studied in the treatment of other conditions and types of cancer.
Fluorouracil is also available in a topical form. For more information, see the Drug Information Summary for Fluorouracil (Topical).
Contra-Indications
- Hypersensitivity to the active component or any of the ingredients
- Pregnancy
- In patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
- caloric undernutrition
- decreased function of bone marrow
- decreased blood platelets
- a significant decrease in certain blood clotting cells called platelets
- low levels of white blood cells
- low levels of a type of white blood cell called neutrophils
- angina, a type of chest pain
- abnormal EKG with QT changes from birth
- bleeding
- throat irritation
- stomatitis, a condition with painful swelling and sores inside the mouth
- stomach or intestinal ulcer
- liver problems
- bleeding of the stomach or intestines
- decreased kidney function
- erythrodysesthesia or tingling, pain, redness, and edema in the hands and feet
- excessive vomiting
- diarrhea
- pregnancy
- a patient who is producing milk and breastfeeding
- dihydropyrimidine dehydrogenase deficiency
- spread of malignant cancer to the bone marrow
Dosage
Strengths: 5%; 2%; 1%; 0.5%; 4%
Keratosis
- 0.5% cream (microsphere formulation): Apply to the affected area once a day where actinic keratosis lesions appear, using enough to cover the entire area with a thin film
- Duration of therapy: Apply for up to 4 weeks as tolerated; continued treatment up to 4 weeks results in greater lesion reduction; local irritation is not markedly increased by extending treatment from 2 to 4 weeks, and is generally resolved within 2 weeks of cessation of therapy 1%, 2%, 5% cream or 2%, 5% solution: Apply 2 times a day in an amount enough to cover the lesions; continue until the inflammatory response reaches the erosion stage, then discontinue use
- Duration of therapy: 2 to 4 weeks; complete healing of the lesions may not be evident for 1 to 2 months following cessation of therapy
- The response starts with erythema, usually followed by vesiculation, desquamation, erosion and re-epithelialization.
- This drug should not be applied near the eyes, nostrils, or mouth.
- Apply 10 minutes after washing, rinsing, and drying the entire area.
- This drug may be applied using the fingertips.
- Immediately after application, the hands should be thoroughly washed.
- Solar keratoses which do not respond to treatment should be biopsied to confirm the diagnosis.
Basal Cell Carcinoma
- 5% cream or solution:
- Apply 2 times a day in an amount sufficient to cover the lesions; continue until the inflammatory response reaches the erosion stage, then discontinue use
- Duration of therapy: 3 to 6 weeks; however, therapy may be required for as long as 10 to 12 weeks before lesions are obliterated
- Only a 5% cream or solution is recommended to treat superficial basal cell carcinoma.
- The response starts with erythema, usually followed by vesiculation, desquamation, erosion and re-epithelialization.
Administration advice:
- Apply with a nonmetal applicator or glove; if applied with the fingers, the hands should be washed immediately afterward.
- Avoid contact with mucous membranes, eyelids, eyes, nostrils, or mouth.
- Avoid prolonged exposure to ultraviolet light or sunlight.
- Avoid occlusive dressings unless clinically indicated.
General:
- Deep, penetrating, or nodular basal cell and squamous cell carcinomas do not usually respond to this drug; it should be used only as a palliative therapy in such cases where no other form of treatment is possible.
- The 0.5%, 1%, and 2% strengths should not be used in the treatment of basal cell carcinoma.
- When this drug is applied to a lesion, a response occurs with the following sequence: erythema, usually followed by vesiculation, desquamation, erosion, and reepithelialization
Side Effects
The Most Common
- burning, crusting, redness,
- discoloration, irritation, pain,
- itching, rash, or
- soreness at the site of application
- severe stomach pain
- bloody diarrhea
- vomiting
- fever
- chills
- severe red skin rash
- Local pain
- Itchiness
- Burning
- Stinging
- Crusting
- Weeping
- Dermatitis
- Photosensitivity
More Common
- Nausea
- Vomiting
- Diarrhea (see below for details)
- Mucositis
- Headache
- Myelosuppression (see below for details)
- Alopecia (hair loss)
- Photosensitivity
- Hand-foot syndrome
- Maculopapular eruption
- Itch
- Cardiotoxicity (see below for details)
- Persistent hiccups
- Mood disorders (irritability, anxiety, depression)
- skin pain, itching, burning, or irritation;
- skin darkening or scarring;
- skin redness and swelling; or
- small blood vessels under the skin.
Rare
- Oesophagitis
- GI ulceration and bleeding
- Proctitis
- Nail disorders
- Vein pigmentation
- Confusion
- Cerebellar syndrome
- Encephalopathy
- Visual changes
- Photophobia
- Lacrimation (the expulsion of tears without any emotional or physiologic reason)
- Anaphylaxis
- Allergic reactions
- Fever without signs of infection
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abametapir | The serum concentration of Fluorouracil can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Fluorouracil can be increased when combined with Abatacept. |
| Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Fluorouracil. |
| Abemaciclib | Abemaciclib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Abiraterone | The serum concentration of Fluorouracil can be increased when it is combined with Abiraterone. |
| Abrocitinib | The metabolism of Abrocitinib can be decreased when combined with Fluorouracil. |
| Acenocoumarol | The metabolism of Acenocoumarol can be decreased when combined with Fluorouracil. |
| Acetaminophen | The metabolism of Fluorouracil can be decreased when combined with Acetaminophen. |
| Acetohexamide | The metabolism of Acetohexamide can be decreased when combined with Fluorouracil. |
| Acetyldigitoxin | Acetyldigitoxin may decrease the cardiotoxic activities of Fluorouracil. |
| Acetylsalicylic acid | The metabolism of Acetylsalicylic acid can be decreased when combined with Fluorouracil. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Fluorouracil. |
| Acyclovir | The metabolism of Acyclovir can be decreased when combined with Fluorouracil. |
| Adalimumab | The metabolism of Fluorouracil can be increased when combined with Adalimumab. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Adenosine. |
| Adenovirus type 7 | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Fluorouracil. |
| Afatinib | Afatinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Agomelatine | The metabolism of Agomelatine can be decreased when combined with Fluorouracil. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Fluorouracil. |
| Albendazole | The metabolism of Fluorouracil can be increased when combined with Albendazole. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluorouracil. |
| Alectinib | Alectinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Fluorouracil. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluorouracil. |
| Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Fluorouracil. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Fluorouracil. |
| Allantoin | The therapeutic efficacy of Allantoin can be decreased when used in combination with Fluorouracil. |
| Allogeneic processed | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Fluorouracil. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Fluorouracil. |
| Almotriptan | The metabolism of Fluorouracil can be decreased when combined with Almotriptan. |
| Alosetron | The metabolism of Fluorouracil can be decreased when combined with Alosetron. |
| Alpelisib | The metabolism of Fluorouracil can be decreased when combined with Alpelisib. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Fluorouracil. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Fluorouracil. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Fluorouracil. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Amifampridine. |
| Aminophenazone | The metabolism of Fluorouracil can be decreased when combined with Aminophenazone. |
| Aminophylline | The metabolism of Aminophylline can be decreased when combined with Fluorouracil. |
| Amiodarone | The metabolism of Amiodarone can be decreased when combined with Fluorouracil. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Amisulpride. |
| Amitriptyline | The metabolism of Fluorouracil can be decreased when combined with Amitriptyline. |
| Amodiaquine | The metabolism of Fluorouracil can be decreased when combined with Amodiaquine. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Fluorouracil. |
| Amphetamine | The metabolism of Fluorouracil can be decreased when combined with Amphetamine. |
| Amprenavir | The metabolism of Amprenavir can be decreased when combined with Fluorouracil. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluorouracil. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Anagrelide. |
| Anakinra | The metabolism of Fluorouracil can be increased when combined with Anakinra. |
| Anastrozole | The metabolism of Fluorouracil can be decreased when combined with Anastrozole. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Fluorouracil. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Fluorouracil. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Antazoline. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fluorouracil. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Fluorouracil. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Antilymphocyte immunoglobulin (horse). |
| Antipyrine | The metabolism of Fluorouracil can be decreased when combined with Antipyrine. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Fluorouracil. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Antithrombin III human is combined with Fluorouracil. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluorouracil. |
| Apalutamide | The metabolism of Fluorouracil can be decreased when combined with Apalutamide. |
| Apixaban | The metabolism of Fluorouracil can be decreased when combined with Apixaban. |
| Apomorphine | The metabolism of Fluorouracil can be decreased when combined with Apomorphine. |
| Apremilast | The metabolism of Fluorouracil can be increased when combined with Apremilast. |
| Ardeparin | The risk or severity of bleeding can be increased when Ardeparin is combined with Fluorouracil. |
| Arformoterol | The metabolism of Fluorouracil can be decreased when combined with Arformoterol. |
| Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Fluorouracil. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fluorouracil. |
| Aripiprazole lauroxil | The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Fluorouracil. |
| Armodafinil | The metabolism of Fluorouracil can be increased when combined with Armodafinil. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Arsenic trioxide. |
| Artemether | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Artemether. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Articaine. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Asenapine. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Astemizole. |
| COVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Fluorouracil. |
| Asunaprevir | The metabolism of Fluorouracil can be decreased when combined with Asunaprevir. |
| Atazanavir | The metabolism of Fluorouracil can be decreased when combined with Atazanavir. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fluorouracil. |
| Atorvastatin | The metabolism of Fluorouracil can be decreased when combined with Atorvastatin. |
| Atropine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Atropine. |
| Avanafil | Avanafil may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Avapritinib | The metabolism of Avapritinib can be decreased when combined with Fluorouracil. |
| Avatrombopag | The metabolism of Fluorouracil can be increased when combined with Avatrombopag. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Fluorouracil. |
| Azacitidine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Azacitidine. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Fluorouracil. |
| Azathioprine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Azathioprine. |
| Azelastine | The metabolism of Fluorouracil can be decreased when combined with Azelastine. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Fluorouracil. |
| Belinostat | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Belinostat. |
| Belumosudil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Fluorouracil. |
| Bendamustine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bendamustine. |
| Bendroflumethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Fluorouracil. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Fluorouracil. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Benzocaine. |
| Benzthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Fluorouracil. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Benzyl alcohol. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Bepridil. |
| Berotralstat | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Berotralstat. |
| Betamethasone | The metabolism of Fluorouracil can be increased when combined with Betamethasone. |
| Betaxolol | The metabolism of Fluorouracil can be decreased when combined with Betaxolol. |
| Betrixaban | The risk or severity of bleeding can be increased when Betrixaban is combined with Fluorouracil. |
| Bevacizumab | The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Fluorouracil. |
| Bexarotene | The metabolism of Fluorouracil can be decreased when combined with Bexarotene. |
| Bezafibrate | The metabolism of Fluorouracil can be decreased when combined with Bezafibrate. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Fluorouracil. |
| Bimekizumab | The metabolism of Fluorouracil can be increased when combined with Bimekizumab. |
| Binimetinib | The metabolism of Binimetinib can be decreased when combined with Fluorouracil. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Fluorouracil. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluorouracil. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Blinatumomab. |
| Bordetella pertussis | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Fluorouracil. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluorouracil. |
| Bosentan | The metabolism of Bosentan can be decreased when combined with Fluorouracil. |
| Bosutinib | The metabolism of Fluorouracil can be decreased when combined with Bosutinib. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brentuximab vedotin. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Fluorouracil. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Fluorouracil. |
| Brivaracetam | The metabolism of Brivaracetam can be decreased when combined with Fluorouracil. |
| Brodalumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brodalumab. |
| Bromazepam | The metabolism of Bromazepam can be decreased when combined with Fluorouracil. |
| Bromotheophylline | The metabolism of Bromotheophylline can be decreased when combined with Fluorouracil. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Fluorouracil. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Fluorouracil. |
| Budesonide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Fluorouracil can be decreased when combined with Buprenorphine. |
| Bupropion | The metabolism of Bupropion can be decreased when combined with Fluorouracil. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Fluorouracil. |
| Busulfan | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Busulfan. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Butriptyline. |
| Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Fluorouracil. |
| Cabozantinib | The metabolism of Fluorouracil can be decreased when combined with Cabozantinib. |
| Caffeine | The metabolism of Fluorouracil can be decreased when combined with Caffeine. |
| Canakinumab | The metabolism of Fluorouracil can be increased when combined with Canakinumab. |
| Candesartan cilexetil | The metabolism of Fluorouracil can be decreased when combined with Candesartan cilexetil. |
| Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Fluorouracil. |
| Cannabidiol | The metabolism of Fluorouracil can be decreased when combined with Cannabidiol. |
| Capecitabine | The metabolism of Capecitabine can be decreased when combined with Fluorouracil. |
| Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Fluorouracil. |
| Capmatinib | The serum concentration of Fluorouracil can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Capsaicin. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carbamazepine. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Carbinoxamine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carboplatin. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorouracil. |
| Carvedilol | The metabolism of Carvedilol can be decreased when combined with Fluorouracil. |
| Celecoxib | The metabolism of Fluorouracil can be decreased when combined with Celecoxib. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Fluorouracil. |
| Cenobamate | The metabolism of Fluorouracil can be increased when combined with Cenobamate. |
| Ceritinib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ceritinib. |
| Cerivastatin | The metabolism of Fluorouracil can be decreased when combined with Cerivastatin. |
| Certolizumab pegol | The metabolism of Fluorouracil can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Fluorouracil. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluorouracil. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluorouracil. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Fluorouracil. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Chloroprocaine. |
| Chloroquine | The metabolism of Fluorouracil can be decreased when combined with Chloroquine. |
| Chlorothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Fluorouracil. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Chlorpheniramine. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Fluorouracil. |
| Chlorpropamide | The metabolism of Chlorpropamide can be decreased when combined with Fluorouracil. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Fluorouracil. |
| Chlorzoxazone | The metabolism of Fluorouracil can be decreased when combined with Chlorzoxazone. |
| Cholesterol | Cholesterol may increase the excretion rate of Fluorouracil which could result in a lower serum level and potentially a reduction in efficacy. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ciclesonide. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Fluorouracil. |
| Cimetidine | The serum concentration of Fluorouracil can be increased when it is combined with Cimetidine. |
| Cinacalcet | The metabolism of Cinacalcet can be decreased when combined with Fluorouracil. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Cinchocaine. |
| Cinnarizine | The metabolism of Fluorouracil can be decreased when combined with Cinnarizine. |
| Cinoxacin | The metabolism of Fluorouracil can be decreased when combined with Cinoxacin. |
| Ciprofloxacin | The metabolism of Fluorouracil can be decreased when combined with Ciprofloxacin. |
| Cisapride | The metabolism of Fluorouracil can be decreased when combined with Cisapride. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Citalopram. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Fluorouracil. |
| Clarithromycin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Clemastine. |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clobetasol propionate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clofarabine. |
| Clofazimine | Clofazimine may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Clofibrate | The metabolism of Fluorouracil can be decreased when combined with Clofibrate. |
| Clomipramine | The metabolism of Clomipramine can be decreased when combined with Fluorouracil. |
| Clonidine | The metabolism of Clonidine can be decreased when combined with Fluorouracil. |
| Clopidogrel | The metabolism of Fluorouracil can be decreased when combined with Clopidogrel. |
| Clostridium tetani | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil. |
| Clozapine | The risk or severity of neutropenia can be increased when Fluorouracil is combined with Clozapine. |
| Cobicistat | Cobicistat may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Cocaine. |
| Conjugated estrogens | The metabolism of Fluorouracil can be decreased when combined with Conjugated estrogens. |
| Corticotropin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil. |
| Crizotinib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Crizotinib. |
| Curcumin | The metabolism of Fluorouracil can be decreased when combined with Curcumin. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fluorouracil. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Fluorouracil. |
| Cyclobenzaprine | The metabolism of Cyclobenzaprine can be decreased when combined with Fluorouracil. |
| Cyclopenthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Fluorouracil. |
| Cyclophosphamide | The metabolism of Fluorouracil can be increased when combined with Cyclophosphamide. |
| Cyclosporine | Fluorouracil may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Fluorouracil. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Fluorouracil. |
| Cyproterone acetate | The metabolism of Fluorouracil can be increased when combined with Cyproterone acetate. |
| Cytarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cytarabine. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Fluorouracil. |
| Dabigatran etexilate | The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Fluorouracil. |
| Dabrafenib | The serum concentration of Fluorouracil can be decreased when it is combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dacarbazine. |
| Daclatasvir | Daclatasvir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Dacomitinib | The metabolism of Dacomitinib can be decreased when combined with Fluorouracil. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dactinomycin. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Fluorouracil. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Fluorouracil. |
| Dantrolene | The therapeutic efficacy of Dantrolene can be decreased when used in combination with Fluorouracil. |
| Dapagliflozin | The metabolism of Fluorouracil can be decreased when combined with Dapagliflozin. |
| Dapsone | The metabolism of Fluorouracil can be decreased when combined with Dapsone. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fluorouracil. |
| Darolutamide | The serum concentration of Fluorouracil can be increased when it is combined with Darolutamide. |
| Dasabuvir | The metabolism of Fluorouracil can be decreased when combined with Dasabuvir. |
| Dasatinib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Decitabine. |
| Deferasirox | The serum concentration of Fluorouracil can be increased when it is combined with Deferasirox. |
| Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Fluorouracil. |
| Deflazacort | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Deflazacort. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluorouracil. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Fluorouracil. |
| Delamanid | Fluorouracil may increase the QTc-prolonging activities of Delamanid. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Fluorouracil. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Fluorouracil. |
| Desipramine | The risk or severity of QTc prolongation can be increased when Desipramine is combined with Fluorouracil. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Fluorouracil. |
| Deslanoside | Deslanoside may decrease the cardiotoxic activities of Fluorouracil. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Desloratadine. |
| Desogestrel | The metabolism of Desogestrel can be decreased when combined with Fluorouracil. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Desoximetasone. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Deucravacitinib. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Deutetrabenazine. |
| Dexamethasone | The metabolism of Fluorouracil can be increased when combined with Dexamethasone. |
| Dexamethasone acetate | Dexamethasone acetate may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fluorouracil. |
| Dexchlorpheniramine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dexchlorpheniramine maleate. |
| Dexfenfluramine | The metabolism of Dexfenfluramine can be decreased when combined with Fluorouracil. |
| Dexibuprofen | The metabolism of Fluorouracil can be decreased when combined with Dexibuprofen. |
| Dexmedetomidine | The metabolism of Fluorouracil can be decreased when combined with Dexmedetomidine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluorouracil. |
| Dextran | The risk or severity of bleeding can be increased when Dextran is combined with Fluorouracil. |
| Dextromethorphan | The metabolism of Dextromethorphan can be decreased when combined with Fluorouracil. |
| Diacerein | The metabolism of Fluorouracil can be decreased when combined with Diacerein. |
| Diazepam | The metabolism of Diazepam can be decreased when combined with Fluorouracil. |
| Diclofenac | The metabolism of Fluorouracil can be decreased when combined with Diclofenac. |
| Dicoumarol | The metabolism of Dicoumarol can be decreased when combined with Fluorouracil. |
| Diethylstilbestrol | The metabolism of Fluorouracil can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Difluocortolone. |
| Digitoxin | Digitoxin may decrease the cardiotoxic activities of Fluorouracil. |
| Digoxin | Digoxin may decrease the cardiotoxic activities of Fluorouracil. |
| Dihydralazine | The metabolism of Fluorouracil can be decreased when combined with Dihydralazine. |
| Diltiazem | The metabolism of Fluorouracil can be decreased when combined with Diltiazem. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dimenhydrinate. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dimethyl fumarate. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dinutuximab. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Diphenhydramine. |
| Dipyridamole | The risk or severity of bleeding can be increased when Dipyridamole is combined with Fluorouracil. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Diroximel fumarate. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Disopyramide. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Fluorouracil. |
| Docetaxel | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Docetaxel. |
| Doconexent | The metabolism of Doconexent can be decreased when combined with Fluorouracil. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dofetilide. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dolasetron. |
| Domperidone | The metabolism of Fluorouracil can be decreased when combined with Domperidone. |
| Donepezil | The metabolism of Donepezil can be decreased when combined with Fluorouracil. |
| Dosulepin | The metabolism of Fluorouracil can be decreased when combined with Dosulepin. |
| Doxazosin | The metabolism of Doxazosin can be decreased when combined with Fluorouracil. |
| Doxepin | The metabolism of Doxepin can be decreased when combined with Fluorouracil. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Doxorubicin. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Fluorouracil. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Fluorouracil. |
| Dronedarone | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dronedarone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Fluorouracil. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fluorouracil. |
| Duloxetine | The metabolism of Duloxetine can be decreased when combined with Fluorouracil. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Dyclonine. |
| Ebastine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Fluorouracil. |
| Ebola Zaire vaccine | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Fluorouracil. |
| Eculizumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Eculizumab. |
| Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Fluorouracil. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Fluorouracil. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluorouracil. |
| Efavirenz | The metabolism of Fluorouracil can be decreased when combined with Efavirenz. |
| Elagolix | The metabolism of Fluorouracil can be decreased when combined with Elagolix. |
| Elbasvir | Elbasvir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Eletriptan | The metabolism of Fluorouracil can be increased when combined with Eletriptan. |
| Eliglustat | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Eliglustat. |
| Eltrombopag | The metabolism of Fluorouracil can be decreased when combined with Eltrombopag. |
| Emapalumab | The metabolism of Fluorouracil can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Emedastine. |
| Enasidenib | The metabolism of Fluorouracil can be decreased when combined with Enasidenib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Fluorouracil. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Encorafenib. |
| Enoxacin | The metabolism of Fluorouracil can be decreased when combined with Enoxacin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Fluorouracil. |
| Entecavir | The metabolism of Fluorouracil can be decreased when combined with Entecavir. |
| Entrectinib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Entrectinib. |
| Enzalutamide | The metabolism of Fluorouracil can be decreased when combined with Enzalutamide. |
| Epinastine | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Fluorouracil. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluorouracil. |
| Epoprostenol | The risk or severity of bleeding can be increased when Epoprostenol is combined with Fluorouracil. |
| Eptifibatide | The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluorouracil. |
| Erdafitinib | The metabolism of Erdafitinib can be decreased when combined with Fluorouracil. |
| Eribulin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Eribulin. |
| Erlotinib | The metabolism of Fluorouracil can be decreased when combined with Erlotinib. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Fluorouracil. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fluorouracil. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Escitalopram. |
| Esketamine | The metabolism of Esketamine can be decreased when combined with Fluorouracil. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Fluorouracil. |
| Estradiol | The metabolism of Fluorouracil can be decreased when combined with Estradiol. |
| Estradiol acetate | The metabolism of Fluorouracil can be decreased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Fluorouracil can be decreased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Fluorouracil can be decreased when combined with Estradiol cypionate. |
| Estradiol dienanthate | The metabolism of Fluorouracil can be decreased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Fluorouracil can be decreased when combined with Estradiol valerate. |
| Estramustine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Estramustine. |
| Estrone sulfate | The metabolism of Fluorouracil can be decreased when combined with Estrone sulfate. |
| Eszopiclone | The metabolism of Fluorouracil can be decreased when combined with Eszopiclone. |
| Etanercept | The metabolism of Fluorouracil can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Fluorouracil can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Ethanol can be decreased when combined with Fluorouracil. |
| Ethinylestradiol | The metabolism of Fluorouracil can be decreased when combined with Ethinylestradiol. |
| Ethosuximide | The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Fluorouracil. |
| Ethotoin | The therapeutic efficacy of Ethotoin can be decreased when used in combination with Fluorouracil. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Etidocaine. |
| Etodolac | The metabolism of Etodolac can be decreased when combined with Fluorouracil. |
| Etoposide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Etoposide. |
| Etoricoxib | The metabolism of Etoricoxib can be decreased when combined with Fluorouracil. |
| Etravirine | The metabolism of Etravirine can be decreased when combined with Fluorouracil. |
| Everolimus | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Everolimus. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Fluorouracil. |
| Famotidine | The metabolism of Fluorouracil can be decreased when combined with Famotidine. |
| Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Fluorouracil. |
| Favipiravir | The metabolism of Fluorouracil can be decreased when combined with Favipiravir. |
| Febuxostat | The excretion of Fluorouracil can be decreased when combined with Febuxostat. |
| Fedratinib | Fedratinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Felbamate | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Fluorouracil. |
| Felodipine | The metabolism of Fluorouracil can be decreased when combined with Felodipine. |
| Fenfluramine | The metabolism of Fenfluramine can be decreased when combined with Fluorouracil. |
| Fenofibrate | The metabolism of Fluorouracil can be decreased when combined with Fenofibrate. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fexinidazole. |
| Filgotinib | The serum concentration of Fluorouracil can be increased when it is combined with Filgotinib. |
| Finerenone | The metabolism of Fluorouracil can be decreased when combined with Finerenone. |
| Fingolimod | Fluorouracil may increase the immunosuppressive activities of Fingolimod. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Flecainide. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluorouracil. |
| Fluconazole | The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Fluorouracil. |
| Flucytosine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Flucytosine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fludarabine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fludrocortisone. |
| Fluindione | The metabolism of Fluindione can be decreased when combined with Fluorouracil. |
| Flunarizine | The metabolism of Fluorouracil can be decreased when combined with Flunarizine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Fluorouracil. |
| Flunitrazepam | The metabolism of Fluorouracil can be decreased when combined with Flunitrazepam. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocinolone acetonide. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocinonide. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Fluorouracil. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Fluorouracil. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Flupentixol. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluprednisolone. |
| Flurazepam | The metabolism of Fluorouracil can be decreased when combined with Flurazepam. |
| Flurbiprofen | The metabolism of Flurbiprofen can be decreased when combined with Fluorouracil. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fluspirilene. |
| Flutamide | The metabolism of Fluorouracil can be decreased when combined with Flutamide. |
| Fluticasone | The metabolism of Fluorouracil can be decreased when combined with Fluticasone. |
| Fluticasone furoate | The metabolism of Fluorouracil can be decreased when combined with Fluticasone furoate. |
| Fluticasone propionate | The metabolism of Fluorouracil can be decreased when combined with Fluticasone propionate. |
| Fluvastatin | The metabolism of Fluorouracil can be decreased when combined with Fluvastatin. |
| Fluvoxamine | The metabolism of Fluorouracil can be decreased when combined with Fluvoxamine. |
| Folic acid | The risk or severity of adverse effects can be increased when Folic acid is combined with Fluorouracil. |
| Fomepizole | The metabolism of Fluorouracil can be decreased when combined with Fomepizole. |
| Fondaparinux | The risk or severity of bleeding can be increased when Fondaparinux is combined with Fluorouracil. |
| Fostamatinib | Fostamatinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Fostemsavir | Fostemsavir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Frovatriptan | The metabolism of Frovatriptan can be decreased when combined with Fluorouracil. |
| Furosemide | The therapeutic efficacy of Furosemide can be decreased when used in combination with Fluorouracil. |
| Fusidic acid | Fusidic acid may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Gadobenic acid. |
| Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fluorouracil. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Gallium nitrate. |
| Gatifloxacin | The metabolism of Fluorouracil can be decreased when combined with Gatifloxacin. |
| Gefitinib | Gefitinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Gemcitabine | The serum concentration of Fluorouracil can be increased when it is combined with Gemcitabine. |
| Gemfibrozil | The metabolism of Fluorouracil can be decreased when combined with Gemfibrozil. |
| Gemifloxacin | The metabolism of Fluorouracil can be decreased when combined with Gemifloxacin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil. |
| Gilteritinib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Gilteritinib. |
| Gimeracil | The serum concentration of Fluorouracil can be increased when it is combined with Gimeracil. |
| Givosiran | The serum concentration of Fluorouracil can be increased when it is combined with Givosiran. |
| Glasdegib | The metabolism of Fluorouracil can be decreased when combined with Glasdegib. |
| Glatiramer | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Glatiramer. |
| Glecaprevir | Glecaprevir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Gliclazide | The metabolism of Gliclazide can be decreased when combined with Fluorouracil. |
| Glimepiride | The metabolism of Glimepiride can be decreased when combined with Fluorouracil. |
| Glipizide | The metabolism of Glipizide can be decreased when combined with Fluorouracil. |
| Gliquidone | The metabolism of Gliquidone can be decreased when combined with Fluorouracil. |
| Glyburide | The metabolism of Glyburide can be decreased when combined with Fluorouracil. |
| Golimumab | The metabolism of Fluorouracil can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluorouracil. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Granisetron. |
| Grazoprevir | Grazoprevir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Grepafloxacin. |
| Guanabenz | The metabolism of Guanabenz can be decreased when combined with Fluorouracil. |
| Guselkumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Guselkumab. |
| Haemophilus | The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Fluorouracil. |
| Halofantrine | The metabolism of Fluorouracil can be decreased when combined with Halofantrine. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Haloperidol. |
| Halothane | The metabolism of Fluorouracil can be decreased when combined with Halothane. |
| Heparin | The therapeutic efficacy of Heparin can be decreased when used in combination with Fluorouracil. |
| Hepatitis A Vaccine | The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluorouracil. |
| Hepatitis B Vaccine | The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fluorouracil. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Fluorouracil. |
| Human adenovirus | The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Fluorouracil. |
| Hydrochlorothiazide | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Fluorouracil. |
| Hydrocortisone | The metabolism of Fluorouracil can be increased when combined with Hydrocortisone. |
| Hydrocortisone acetate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone acetate. |
| Hydrocortisone butyrate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone butyrate. |
| Hydrocortisone succinate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydrocortisone succinate. |
| Hydroflumethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Fluorouracil. |
| Hydromorphone | The metabolism of Hydromorphone can be decreased when combined with Fluorouracil. |
| Hydroxychloroquine | The metabolism of Fluorouracil can be decreased when combined with Hydroxychloroquine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydroxyurea. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Fluorouracil. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluorouracil. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ibrutinib. |
| Ibuprofen | The metabolism of Fluorouracil can be decreased when combined with Ibuprofen. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ibutilide. |
| Icosapent ethyl | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Fluorouracil. |
| Idarubicin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idarubicin. |
| Idelalisib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idelalisib. |
| Ifosfamide | The metabolism of Fluorouracil can be increased when combined with Ifosfamide. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Iloperidone. |
| Iloprost | The risk or severity of bleeding can be increased when Iloprost is combined with Fluorouracil. |
| Imatinib | The metabolism of Fluorouracil can be decreased when combined with Imatinib. |
| Imipramine | The metabolism of Fluorouracil can be decreased when combined with Imipramine. |
| Indacaterol | The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fluorouracil. |
| Indapamide | The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fluorouracil. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorouracil. |
| Inebilizumab | The risk or severity of infection can be increased when Fluorouracil is combined with Inebilizumab. |
| Infliximab | The metabolism of Fluorouracil can be increased when combined with Infliximab. |
| Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Fluorouracil. |
| Methylene blue | The metabolism of Fluorouracil can be decreased when combined with Methylene blue. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Methylprednisolone. |
| Metoclopramide | The metabolism of Metoclopramide can be decreased when combined with Fluorouracil. |
| Metreleptin | The metabolism of Fluorouracil can be increased when combined with Metreleptin. |
| Metronidazole | The serum concentration of Fluorouracil can be increased when it is combined with Metronidazole. |
| Metyrapone | The metabolism of Fluorouracil can be decreased when combined with Metyrapone. |
| Mexiletine | The metabolism of Fluorouracil can be decreased when combined with Mexiletine. |
| Mianserin | The metabolism of Mianserin can be decreased when combined with Fluorouracil. |
| Miconazole | The metabolism of Fluorouracil can be decreased when combined with Miconazole. |
| Mifepristone | The serum concentration of Fluorouracil can be increased when it is combined with Mifepristone. |
| Mirabegron | The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Fluorouracil. |
| Mirtazapine | The metabolism of Fluorouracil can be decreased when combined with Mirtazapine. |
| Mitapivat | The metabolism of Fluorouracil can be increased when combined with Mitapivat. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluorouracil. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mitoxantrone. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mizolastine. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mobocertinib. |
| COVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Fluorouracil. |
| Modified vaccinia ankara | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Fluorouracil. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Fluorouracil. |
| Mometasone furoate | The metabolism of Fluorouracil can be decreased when combined with Mometasone furoate. |
| Monomethyl fumarate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Monomethyl fumarate. |
| Montelukast | The metabolism of Fluorouracil can be decreased when combined with Montelukast. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Fluorouracil. |
| Morphine | The metabolism of Fluorouracil can be decreased when combined with Morphine. |
| Mosunetuzumab | The metabolism of Fluorouracil can be decreased when combined with Mosunetuzumab. |
| Moxifloxacin | The metabolism of Fluorouracil can be decreased when combined with Moxifloxacin. |
| Mumps virus | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Fluorouracil. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fluorouracil. |
| Mycophenolate mofetil | The metabolism of Fluorouracil can be decreased when combined with Mycophenolate mofetil. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mycophenolic acid. |
| Nabilone | The metabolism of Nabilone can be decreased when combined with Fluorouracil. |
| Nabumetone | The metabolism of Fluorouracil can be decreased when combined with Nabumetone. |
| Nadroparin | The risk or severity of bleeding can be increased when Nadroparin is combined with Fluorouracil. |
| Nafcillin | The metabolism of Fluorouracil can be increased when combined with Nafcillin. |
| Nalidixic acid | The metabolism of Fluorouracil can be decreased when combined with Nalidixic acid. |
| Naproxen | The metabolism of Fluorouracil can be decreased when combined with Naproxen. |
| Natalizumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab. |
| Nateglinide | The metabolism of Nateglinide can be decreased when combined with Fluorouracil. |
| Nelarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Nelarabine. |
| Nelfinavir | Nelfinavir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Neomycin | Neomycin can cause a decrease in the absorption of Fluorouracil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Netupitant | The metabolism of Netupitant can be decreased when combined with Fluorouracil. |
| Nevirapine | The metabolism of Fluorouracil can be decreased when combined with Nevirapine. |
| Nicardipine | The metabolism of Fluorouracil can be decreased when combined with Nicardipine. |
| Niclosamide | The metabolism of Fluorouracil can be decreased when combined with Niclosamide. |
| Nicotine | The metabolism of Fluorouracil can be decreased when combined with Nicotine. |
| Nifedipine | The metabolism of Fluorouracil can be decreased when combined with Nifedipine. |
| Nilotinib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Nilotinib. |
| Nilutamide | The metabolism of Fluorouracil can be decreased when combined with Nilutamide. |
| Nilvadipine | The metabolism of Fluorouracil can be decreased when combined with Nilvadipine. |
| Nimesulide | The risk or severity of bleeding can be increased when Nimesulide is combined with Fluorouracil. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Fluorouracil. |
| Nitrendipine | The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Fluorouracil. |
| Nitrofurantoin | The therapeutic efficacy of Nitrofurantoin can be decreased when used in combination with Fluorouracil. |
| Norfloxacin | The metabolism of Fluorouracil can be decreased when combined with Norfloxacin. |
| Norgestimate | The metabolism of Norgestimate can be decreased when combined with Fluorouracil. |
| Nortriptyline | The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Fluorouracil. |
| Novobiocin | Novobiocin may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Fluorouracil. |
| Obeticholic acid | The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Fluorouracil. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Obinutuzumab. |
| Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Fluorouracil. |
| Octreotide | The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluorouracil. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ofatumumab. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ofloxacin. |
| Olanzapine | The metabolism of Fluorouracil can be decreased when combined with Olanzapine. |
| Olaparib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Olaparib. |
| Olodaterol | The metabolism of Fluorouracil can be decreased when combined with Olodaterol. |
| Ombitasvir | The metabolism of Fluorouracil can be decreased when combined with Ombitasvir. |
| Omeprazole | The metabolism of Fluorouracil can be decreased when combined with Omeprazole. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ondansetron. |
| Orphenadrine | The metabolism of Fluorouracil can be decreased when combined with Orphenadrine. |
| Osilodrostat | The serum concentration of Fluorouracil can be increased when it is combined with Osilodrostat. |
| Osimertinib | The serum concentration of Fluorouracil can be decreased when it is combined with Osimertinib. |
| Ospemifene | The metabolism of Ospemifene can be decreased when combined with Fluorouracil. |
| Oteseconazole | The serum concentration of Fluorouracil can be increased when it is combined with Oteseconazole. |
| Ouabain | Ouabain may decrease the cardiotoxic activities of Fluorouracil. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluorouracil. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Oxatomide. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Oxetacaine. |
| Oxtriphylline | The metabolism of Oxtriphylline can be decreased when combined with Fluorouracil. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Fluorouracil can be decreased when combined with Oxybutynin. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluorouracil. |
| Ozanimod | The metabolism of Fluorouracil can be decreased when combined with Ozanimod. |
| Paclitaxel | The metabolism of Paclitaxel can be decreased when combined with Fluorouracil. |
| Pacritinib | The serum concentration of Fluorouracil can be increased when it is combined with Pacritinib. |
| Palbociclib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Palbociclib. |
| Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Fluorouracil. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Paliperidone. |
| Panobinostat | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Panobinostat. |
| Pantoprazole | Pantoprazole may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Papaverine. |
| Paramethadione | The metabolism of Fluorouracil can be decreased when combined with Paramethadione. |
| Parecoxib | The metabolism of Parecoxib can be decreased when combined with Fluorouracil. |
| Paritaprevir | Paritaprevir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Parnaparin | The risk or severity of bleeding can be increased when Parnaparin is combined with Fluorouracil. |
| Paroxetine | The metabolism of Paroxetine can be decreased when combined with Fluorouracil. |
| Pentoxifylline | The metabolism of Pentoxifylline can be decreased when combined with Fluorouracil. |
| Perampanel | The metabolism of Perampanel can be decreased when combined with Fluorouracil. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Perflutren. |
| Perhexiline | The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Fluorouracil. |
| Perphenazine | The metabolism of Perphenazine can be decreased when combined with Fluorouracil. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Fluorouracil. |
| Pertuzumab | The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Pertuzumab. |
| Phenindione | The risk or severity of bleeding can be increased when Fluorouracil is combined with Phenindione. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fluorouracil. |
| Phenobarbital | The metabolism of Fluorouracil can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Fluorouracil. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluorouracil. |
| Phenylbutazone | The metabolism of Phenylbutazone can be decreased when combined with Fluorouracil. |
| Phenylephrine | The metabolism of Fluorouracil can be increased when combined with Phenylephrine. |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Fluorouracil. |
| Pibrentasvir | Pibrentasvir may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Pilocarpine | The metabolism of Fluorouracil can be decreased when combined with Pilocarpine. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluorouracil. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Pimozide. |
| Pinaverium | The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Fluorouracil. |
| Pioglitazone | The metabolism of Fluorouracil can be decreased when combined with Pioglitazone. |
| Piperaquine | The metabolism of Piperaquine can be decreased when combined with Fluorouracil. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pirfenidone. |
| Piroxicam | The metabolism of Fluorouracil can be decreased when combined with Piroxicam. |
| Pitavastatin | The metabolism of Fluorouracil can be decreased when combined with Pitavastatin. |
| Pitolisant | Fluorouracil may increase the QTc-prolonging activities of Pitolisant. |
| Polythiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Fluorouracil. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pomalidomide. |
| Ponatinib | The metabolism of Ponatinib can be decreased when combined with Fluorouracil. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Fluorouracil. |
| Posaconazole | The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Fluorouracil. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pralatrexate. |
| Pralsetinib | The metabolism of Fluorouracil can be decreased when combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Pramocaine. |
| Prasugrel | The metabolism of Prasugrel can be decreased when combined with Fluorouracil. |
| Pravastatin | Pravastatin may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Praziquantel | The metabolism of Praziquantel can be decreased when combined with Fluorouracil. |
| Prednisolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednisolone. |
| Prednisolone | The metabolism of Fluorouracil can be increased when combined with Prednisolone phosphate. |
| Prednisone | The metabolism of Fluorouracil can be increased when combined with Prednisone. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Fluorouracil. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Prenylamine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Prilocaine. |
| Primaquine | The metabolism of Fluorouracil can be increased when combined with Primaquine. |
| Primidone | The metabolism of Fluorouracil can be increased when combined with Primidone. |
| Probenecid | The metabolism of Fluorouracil can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Probucol. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Procainamide. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Procaine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Procarbazine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Fluorouracil. |
| Progesterone | The metabolism of Fluorouracil can be increased when combined with Progesterone. |
| Proguanil | The metabolism of Proguanil can be decreased when combined with Fluorouracil. |
| Promazine | The metabolism of Fluorouracil can be decreased when combined with Promazine. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Fluorouracil. |
| Propafenone | The metabolism of Fluorouracil can be decreased when combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Proparacaine. |
| Propofol | The metabolism of Fluorouracil can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Propoxycaine. |
| Propranolol | The metabolism of Propranolol can be decreased when combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Propylthiouracil. |
| Protein C | The risk or severity of bleeding can be increased when Protein C is combined with Fluorouracil. |
| Protein S human | The risk or severity of bleeding can be increased when Protein S human is combined with Fluorouracil. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Fluorouracil. |
| Pyrimethamine | The metabolism of Fluorouracil can be decreased when combined with Pyrimethamine. |
| Quazepam | The metabolism of Quazepam can be decreased when combined with Fluorouracil. |
| Quetiapine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Quetiapine. |
| Quinidine | The metabolism of Fluorouracil can be decreased when combined with Quinidine. |
| Quinine | The metabolism of Fluorouracil can be decreased when combined with Quinine. |
| Rabeprazole | Rabeprazole may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Rabies immune | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Fluorouracil. |
| inactivated antigen | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fluorouracil. |
| Rabies virus | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Fluorouracil. |
| Raloxifene | The metabolism of Fluorouracil can be decreased when combined with Raloxifene. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluorouracil. |
| Ramelteon | The metabolism of Ramelteon can be decreased when combined with Fluorouracil. |
| Ranitidine | The metabolism of Ranitidine can be decreased when combined with Fluorouracil. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Fluorouracil. |
| Rasagiline | The metabolism of Rasagiline can be decreased when combined with Fluorouracil. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ravulizumab. |
| Regorafenib | Regorafenib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Relugolix | The risk or severity of QTc prolongation can be increased when Relugolix is combined with Fluorouracil. |
| Repaglinide | The metabolism of Fluorouracil can be decreased when combined with Repaglinide. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ribociclib. |
| Rifabutin | The metabolism of Fluorouracil can be increased when combined with Rifabutin. |
| Rifampicin | The metabolism of Fluorouracil can be increased when combined with Rifampicin. |
| Rifamycin | The metabolism of Fluorouracil can be decreased when combined with Rifamycin. |
| Rifapentine | The metabolism of Fluorouracil can be increased when combined with Rifapentine. |
| Rilonacept | The metabolism of Fluorouracil can be increased when combined with Rilonacept. |
| Rilpivirine | The metabolism of Fluorouracil can be decreased when combined with Rilpivirine. |
| Riluzole | The metabolism of Riluzole can be decreased when combined with Fluorouracil. |
| Riociguat | The metabolism of Fluorouracil can be decreased when combined with Riociguat. |
| Ripretinib | Ripretinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Risankizumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Risankizumab. |
| Risperidone | The risk or severity of QTc prolongation can be increased when Risperidone is combined with Fluorouracil. |
| Ritonavir | The metabolism of Fluorouracil can be decreased when combined with Ritonavir. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fluorouracil. |
| Rivaroxaban | The risk or severity of bleeding can be increased when Rivaroxaban is combined with Fluorouracil. |
| Rofecoxib | The metabolism of Fluorouracil can be decreased when combined with Rofecoxib. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Fluorouracil. |
| Rolapitant | Rolapitant may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Romidepsin. |
| Ropeginterferon | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Ropivacaine. |
| Rosiglitazone | The metabolism of Fluorouracil can be decreased when combined with Rosiglitazone. |
| Rosoxacin | The metabolism of Fluorouracil can be decreased when combined with Rosoxacin. |
| Rosuvastatin | The metabolism of Rosuvastatin can be decreased when combined with Fluorouracil. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Fluorouracil. |
| Roxadustat | The serum concentration of Fluorouracil can be increased when it is combined with Roxadustat. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Roxithromycin. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Fluorouracil. |
| Rucaparib | The metabolism of Fluorouracil can be decreased when combined with Rucaparib. |
| Rupatadine | The metabolism of Rupatadine can be decreased when combined with Fluorouracil. |
| Ruxolitinib | The metabolism of Ruxolitinib can be decreased when combined with Fluorouracil. |
| Safinamide | Safinamide may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fluorouracil. |
| Salicylic acid | The metabolism of Salicylic acid can be decreased when combined with Fluorouracil. |
| Salmeterol | The metabolism of Fluorouracil can be decreased when combined with Salmeterol. |
| Saquinavir | The metabolism of Fluorouracil can be decreased when combined with Saquinavir. |
| Sarilumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sarilumab. |
| Satralizumab | The serum concentration of Fluorouracil can be decreased when it is combined with Satralizumab. |
| Secobarbital | The metabolism of Fluorouracil can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Fluorouracil can be increased when combined with Secukinumab. |
| Selegiline | The metabolism of Fluorouracil can be decreased when combined with Selegiline. |
| Selexipag | The metabolism of Fluorouracil can be decreased when combined with Selexipag. |
| Selpercatinib | The serum concentration of Fluorouracil can be increased when it is combined with Selpercatinib. |
| Selumetinib | The metabolism of Fluorouracil can be decreased when combined with Selumetinib. |
| Sertraline | The metabolism of Sertraline can be decreased when combined with Fluorouracil. |
| Sevoflurane | The metabolism of Fluorouracil can be decreased when combined with Sevoflurane. |
| Sildenafil | The metabolism of Sildenafil can be decreased when combined with Fluorouracil. |
| Siltuximab | The metabolism of Fluorouracil can be increased when combined with Siltuximab. |
| Simeprevir | The metabolism of Fluorouracil can be decreased when combined with Simeprevir. |
| Simvastatin | The metabolism of Fluorouracil can be decreased when combined with Simvastatin. |
| Siponimod | The metabolism of Siponimod can be decreased when combined with Fluorouracil. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fluorouracil. |
| Sirolimus | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sirolimus. |
| Sitagliptin | The metabolism of Fluorouracil can be decreased when combined with Sitagliptin. |
| Sitaxentan | The metabolism of Sitaxentan can be decreased when combined with Fluorouracil. |
| Smallpox | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Fluorouracil. |
| Sodium citrate | The risk or severity of bleeding can be increased when Sodium citrate is combined with Fluorouracil. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Fluorouracil. |
| Somapacitan | The metabolism of Fluorouracil can be increased when combined with Somapacitan. |
| Somatotropin | The metabolism of Fluorouracil can be increased when combined with Somatotropin. |
| Somatrem | The metabolism of Fluorouracil can be increased when combined with Somatrem. |
| Somatrogon | The metabolism of Fluorouracil can be increased when combined with Somatrogon. |
| Sorafenib | The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Fluorouracil. |
| Sotagliflozin | Sotagliflozin may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sotalol. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sparfloxacin. |
| Spesolimab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Spesolimab. |
| Spironolactone | The metabolism of Fluorouracil can be decreased when combined with Spironolactone. |
| Stiripentol | The metabolism of Fluorouracil can be decreased when combined with Stiripentol. |
| Streptokinase | The risk or severity of bleeding can be increased when Streptokinase is combined with Fluorouracil. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluorouracil. |
| Sulfadiazine | The metabolism of Fluorouracil can be decreased when combined with Sulfadiazine. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluorouracil. |
| Sulfaphenazole | The metabolism of Fluorouracil can be decreased when combined with Sulfaphenazole. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sulfasalazine. |
| Sulfinpyrazone | The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Fluorouracil. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Fluorouracil. |
| Sulodexide | The risk or severity of bleeding can be increased when Sulodexide is combined with Fluorouracil. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Fluorouracil. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sultopride. |
| Sunitinib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sunitinib. |
| Tacrine | The metabolism of Fluorouracil can be decreased when combined with Tacrine. |
| Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Fluorouracil. |
| Tafamidis | The serum concentration of Fluorouracil can be increased when it is combined with Tafamidis. |
| Tamoxifen | The metabolism of Fluorouracil can be decreased when combined with Tamoxifen. |
| Tasimelteon | The metabolism of Tasimelteon can be decreased when combined with Fluorouracil. |
| Taurocholic acid | Taurocholic acid may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Tazarotene | The metabolism of Fluorouracil can be decreased when combined with Tazarotene. |
| Tecovirimat | The metabolism of Fluorouracil can be increased when combined with Tecovirimat. |
| Tedizolid phosphate | The risk or severity of myelosuppression can be increased when Fluorouracil is combined with Tedizolid phosphate. |
| Tegafur | The metabolism of Tegafur can be decreased when combined with Fluorouracil. |
| Tegafur-uracil | The metabolism of Fluorouracil can be decreased when combined with Tegafur-uracil. |
| Tegaserod | The metabolism of Fluorouracil can be decreased when combined with Tegaserod. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Telavancin. |
| Telithromycin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Telithromycin. |
| Telmisartan | Telmisartan may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Temozolomide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Temsirolimus. |
| Tenoxicam | The metabolism of Tenoxicam can be decreased when combined with Fluorouracil. |
| Tepotinib | Tepotinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Teprotumumab. |
| Terbinafine | The metabolism of Fluorouracil can be decreased when combined with Terbinafine. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluorouracil. |
| Terfenadine | The metabolism of Fluorouracil can be decreased when combined with Terfenadine. |
| Teriflunomide | The serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Terlipressin. |
| Testosterone | The metabolism of Testosterone can be decreased when combined with Fluorouracil. |
| Testosterone | The metabolism of Fluorouracil can be decreased when combined with Testosterone cypionate. |
| Testosterone | The metabolism of Fluorouracil can be decreased when combined with Testosterone enanthate. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Tetrabenazine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Tetracaine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Thalidomide. |
| Theophylline | The metabolism of Fluorouracil can be decreased when combined with Theophylline. |
| Thiabendazole | The metabolism of Fluorouracil can be decreased when combined with Thiabendazole. |
| Thiamylal | The metabolism of Thiamylal can be decreased when combined with Fluorouracil. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Thioridazine. |
| Thiotepa | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Thiotepa. |
| Thiothixene | The metabolism of Thiothixene can be decreased when combined with Fluorouracil. |
| Ticagrelor | The risk or severity of bleeding can be increased when Ticagrelor is combined with Fluorouracil. |
| Tick-borne | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Fluorouracil. |
| Ticlopidine | The metabolism of Fluorouracil can be decreased when combined with Ticlopidine. |
| Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Fluorouracil. |
| Tinzaparin | The risk or severity of bleeding can be increased when Tinzaparin is combined with Fluorouracil. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluorouracil. |
| Tirofiban | The risk or severity of bleeding can be increased when Tirofiban is combined with Fluorouracil. |
| Tivozanib | Tivozanib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Tixocortol | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Tixocortol. |
| Tizanidine | The metabolism of Tizanidine can be decreased when combined with Fluorouracil. |
| Tocainide | The metabolism of Fluorouracil can be decreased when combined with Tocainide. |
| Tocilizumab | The metabolism of Fluorouracil can be increased when combined with Tocilizumab. |
| Tofacitinib | Fluorouracil may increase the immunosuppressive activities of Tofacitinib. |
| Tolazamide | The metabolism of Tolazamide can be decreased when combined with Fluorouracil. |
| Tolbutamide | The metabolism of Fluorouracil can be decreased when combined with Tolbutamide. |
| Tolterodine | The metabolism of Tolterodine can be decreased when combined with Fluorouracil. |
| Topotecan | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Topotecan. |
| Torasemide | The metabolism of Fluorouracil can be decreased when combined with Torasemide. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Toremifene. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluorouracil. |
| Trabectedin | The metabolism of Trabectedin can be decreased when combined with Fluorouracil. |
| Trametinib | The metabolism of Fluorouracil can be decreased when combined with Trametinib. |
| Tranylcypromine | The metabolism of Fluorouracil can be decreased when combined with Tranylcypromine. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Fluorouracil. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trastuzumab emtansine. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluorouracil. |
| Treprostinil | The metabolism of Fluorouracil can be decreased when combined with Treprostinil. |
| Tretinoin | The metabolism of Fluorouracil can be decreased when combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Triamcinolone. |
| Triamterene | The metabolism of Fluorouracil can be decreased when combined with Triamterene. |
| Trichlormethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Fluorouracil. |
| Triclabendazole | The metabolism of Fluorouracil can be decreased when combined with Triclabendazole. |
| Trifluoperazine | The metabolism of Trifluoperazine can be decreased when combined with Fluorouracil. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluorouracil. |
| Triflusal | The risk or severity of bleeding can be increased when Triflusal is combined with Fluorouracil. |
| Trilaciclib | The metabolism of Fluorouracil can be increased when combined with Trilaciclib. |
| Trilostane | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trilostane. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Fluorouracil. |
| Trimethadione | The metabolism of Fluorouracil can be decreased when combined with Trimethadione. |
| Trimethoprim | The metabolism of Fluorouracil can be decreased when combined with Trimethoprim. |
| Trimipramine | The metabolism of Trimipramine can be decreased when combined with Fluorouracil. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Fluorouracil. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluorouracil. |
| Troglitazone | The metabolism of Fluorouracil can be decreased when combined with Troglitazone. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Trovafloxacin. |
| Tucatinib | The metabolism of Fluorouracil can be decreased when combined with Tucatinib. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Fluorouracil. |
| Typhoid Vaccine Live | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Fluorouracil. |
| Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Fluorouracil. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Upadacitinib. |
| Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Fluorouracil. |
| Valdecoxib | The metabolism of Valdecoxib can be decreased when combined with Fluorouracil. |
| Valproic acid | The metabolism of Fluorouracil can be decreased when combined with Valproic acid. |
| Valsartan | The metabolism of Valsartan can be decreased when combined with Fluorouracil. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Vandetanib. |
| Vardenafil | The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Fluorouracil. |
| Varicella zoster vaccine | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Fluorouracil. |
| Varicella zoster vaccine | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Fluorouracil. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vedolizumab. |
| Velpatasvir | The metabolism of Fluorouracil can be decreased when combined with Velpatasvir. |
| Vemurafenib | The serum concentration of Fluorouracil can be increased when it is combined with Vemurafenib. |
| Venetoclax | Venetoclax may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Venlafaxine | Venlafaxine may increase the excretion rate of Fluorouracil which could result in a lower serum level and potentially a reduction in efficacy. |
| Verapamil | The metabolism of Fluorouracil can be decreased when combined with Verapamil. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Fluorouracil. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Fluorouracil. |
| Vilanterol | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vilanterol. |
| Viloxazine | The metabolism of Fluorouracil can be decreased when combined with Viloxazine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Fluorouracil. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Fluorouracil. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Fluorouracil. |
| Vismodegib | Vismodegib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
| Voclosporin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Voclosporin. |
| Vorapaxar | The risk or severity of bleeding can be increased when Vorapaxar is combined with Fluorouracil. |
| Voriconazole | The metabolism of Voriconazole can be decreased when combined with Fluorouracil. |
| Vorinostat | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vorinostat. |
| Vortioxetine | The metabolism of Fluorouracil can be decreased when combined with Vortioxetine. |
Pregnancy and lactation
AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.
Pregnancy
This drug can harm a developing fetus when administered to a pregnant woman. No adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms. One birth defect (ventricular septal defect) and cases of miscarriage have been reported when this drug was applied to mucous membrane areas. Multiple birth defects have been reported in the fetus of a patient treated with the IV formulation.
Lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear.
How should this medicine be used?
Fluorouracil comes as a solution and a cream to apply to the skin. It is usually applied to the affected areas twice a day. To help you remember to use fluorouracil, apply it around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use fluorouracil exactly as directed. Do not apply more or less of it or apply it more often than prescribed by your doctor.
If you are using fluorouracil to treat actinic or solar keratoses, you should continue using it until the lesions start to peel off. This usually takes about 2 to 4 weeks. However, the lesions may not be completely healed until 1 or 2 months after you stop using fluorouracil.
If you are using fluorouracil to treat basal cell carcinoma, you should continue using it until the lesions are gone. This usually takes at least 3 to 6 weeks, but may take as long as 10 to 12 weeks.
During the first few weeks of treatment, the skin lesions and surrounding areas will feel irritated and look red, swollen, and scaly. This is a sign that fluorouracil is working. Do not stop using fluorouracil unless your doctor has told you to do so.
Apply fluorouracil cream with a nonmetal applicator, a glove, or your finger. If you apply fluorouracil cream with your finger, be sure to wash your hands well immediately afterward. Do not cover the treated areas with a bandage or dressing unless your doctor tells you to.
Do not apply fluorouracil cream or topical solution to the eyelids or the eyes, nose, or mouth.
What special precautions should I follow?
Before using fluorouracil,
- tell your doctor and pharmacist if you are allergic to fluorouracil or any other medications.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking, especially other topical medications. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had dihydropyrimidine dehydrogenase (DPD) enzyme deficiency (a lack of a naturally occurring enzyme in your body).
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while using fluorouracil , call your doctor immediately. Fluorouracil can harm the fetus.
- plan to avoid unnecessary or prolonged exposure to sunlight and UV light (such as tanning booths) and to wear protective clothing, sunglasses, and sunscreen. Fluorouracil may make your skin sensitive to sunlight.
References
